参考文献/References:
[1]Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a populationbased study. Lancet,2006,368(9540):1005-1011.
[2]Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J,2007, 28(11):1358-1365.
[3]Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol,2014,63(2):185-186.
[4]Mylotte D, Piazza N. Transcatheter mitral valve implantation: a brief review. Eurolntervention, 2015,11(Suppl W):W67-W70.
[5]Puri R, AbdulJawad Altisent O,del Trigo M, et al. Transcatheter mitral valve implantation for inoperable severely calcified native mitral valve disease : A systematic review. Catheter Cardiovase Interv,2016, 87(3):540-548.
[6]Romeo F, Cammalleri V, Ruvolo G, et al. Transcatheter mitral valve implantation for mitral regurgitation: clinical case description and literature review. J Cardiovasc Med (Hagerstown),2016,17(2):85-91.
[7]Sondergaard L, Brooks M, Ihlemann N, et al. Transcatheter mitral valve implantation via transapical approach: an early experience. Eur J Cardiothorac Surg,2015,48(6):873-877.
[8]Glower DD, Kar S, Trento A, et al. Percutaneous mitral valve repair for mitral regurgitation in highrisk patients: results of the EVEREST Ⅱ study. J Am Coll Cardiol,2014,64(2):172-181.
[9]Cheung A, Webb J, Verheye S, et al. Shortterm results of transapical transcatheter mitral valve implantation for mitral regurgitation. J Am Coll Cardiol,2014,64(17):1814-1819.
[10]Bapat V, Buellesfeld L, Peterson MD, et al. Transcatheter mitral valve implantation (TMVI) using the Edwards FORTIS device. EuroIntervention,2014, 10(Suppl U):U120-U128.
[11]Moat N, Duncan A, Lindsay A, et al. Transcatheter mitral valve replacement for the treatment of mitral regurgitation: inhospital outcomes of an apically tethered device. J Am Coll Cardiol,2015,65(21):2352-2353.
[12]Meredith I, Bapat V, Morriss J, et al. Intrepid transcatheter mitral valve replacement system: technical and product description. EurIntervention,2016,12(Y):Y78-Y80.
[13]Lange R, Piazza N. Highlife transcatheter mitral valve replacement. EuroIntervention,2016,12(Y):Y81-Y83.
[14]Regueiro A, Granada JF, Dagenais F, et al. Transcatheter mitral valve replacement: insights from early clinical experience and future challenges. JACC,2017,69(17):2175-2192.
[15]Abdelghani M, Onuma Y, Zeng Y, et al. The sino medical accufit transcatheter mitral valve implantation system. EuroIntervention,2015,11 (Suppl W):W84-W85.
[16]Zamorano JL, GonzalezGomez A, Laneellotti P. Mitral valve anatomy: Implications for transcatheter mitral valve interventions. Eurolntervention,2014,10(Suppl U):U106-U111.
[17]Maisano F, Alfieri O, Banai S, et al. The future of transcatheter mitral valve interventions: competitive or complementary role of repair vs. replacement. Eur Heart J,2015,36(26):1651-1659.
[18]Regueiro A, Granada JF, Dagenais F, et al. Transcatheter mitral valve replacement: insights from early clinical experience and future challenges. J Am Coll Cardiol,2017,69(17):2175-2192.
[19]Duncan A, Daqa A, Yeh J, et al. Transcatheter mitral valve replacement: longterm outcomes of firstinman experience with an apically tethered devicea case series from a single centre. EuroIntervention,2017,13(9):e1047-e1057.
[20]Capretti G, Urena M, Himbert D, et al. Valve thrombosis after transcatheter mitral valve replacement. J Am Coll Cardiol,2016,68(16):1814-1815.
[21]Peppas A, Furer A, Wilson J, et al. Preclinical in vivo longterm evaluation of the novel MitraSpacer technology: experimental validation in the ovine model. EuroIntervention,2017,13(3):272-279.
[22]Silaschi M, Nicou N, Eskandari M, et al. Dynamic transcatheter mitral valve repair: a new concept to treat functional mitral regurgitation using an adjustable spacer. EuroIntervention,2017,13(3):280-283.
[23]Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med,2015,373(21):2015-2024.
[24]Ruel M, Kulik A, Lam B K, et al. Longterm outcomes of valve replacement with modern prostheses in young adults. Eur J Cardiothorac Surg,2005,27(3):425-433.
[25]潘文志,周达新,葛均波.经导管二尖瓣置换术的应用现状与展望.上海医药, 2017,38(3):11-15.